siRNA Lipid Nanoparticle Formulation
Custom siRNA-LNP FormulationDelivery-Focused OptimizationAnalytical Support from Screening to Scale-Up
Develop research-ready siRNA lipid nanoparticles through an integrated workflow covering payload review, lipid selection, formulation screening, process optimization, purification, and analytical characterization. siRNA-LNP performance depends on more than achieving high RNA encapsulation. Lipid identity, component ratio, mixing conditions, particle size distribution, surface composition, buffer environment, and intracellular release must work together to support reproducible delivery and gene knockdown.
We support customer-supplied siRNA duplexes, chemically modified siRNA, siRNA mixtures, fluorescently labeled siRNA, and exploratory delivery constructs. Projects can be coordinated with broader oligonucleotide-loaded lipid nanoparticle development and informed by application-specific siRNA delivery optimization requirements.
What Problems Can siRNA Lipid Nanoparticles Solve?
Free siRNA is highly charged, sensitive to degradation, and inefficient at crossing cellular membranes. A lipid nanoparticle can protect the duplex, promote cellular uptake, and create an intracellular release pathway, but successful formulation requires careful control of several interdependent variables. A formulation with strong encapsulation may still show weak activity if the particles aggregate, the siRNA is damaged during processing, the surface prevents productive uptake, or the payload remains trapped after endocytosis.
Our siRNA lipid nanoparticle services address these practical development gaps by evaluating the siRNA payload, ionizable lipid system, helper lipid and sterol composition, PEG-lipid content, charge ratio, mixing process, purification method, and final buffer as a connected system. The goal is to identify formulations that are physically measurable, experimentally usable, and aligned with the intended cell model, administration route, or delivery study.
Key Challenges in siRNA-LNP Development
High Encapsulation but Weak Gene Knockdown
Encapsulation efficiency does not directly predict biological activity. Lipid composition, apparent surface charge, endosomal processing, siRNA release, and payload integrity can all affect whether an encapsulated duplex reaches the cytoplasm in a functional state. We connect physicochemical results with uptake and knockdown testing when functional evaluation is included.
Particle Size Changes Between Batches
Small differences in lipid concentration, aqueous-to-organic flow ratio, total mixing rate, pH, temperature, solvent fraction, and equipment geometry can alter particle size and polydispersity. We define controllable process variables and compare repeat preparations rather than relying on a single successful formulation run.
Instability During Purification or Storage
LNPs may change during ethanol removal, buffer exchange, concentration, filtration, freeze-thaw handling, or exposure to biological media. Purification and buffer conditions are therefore developed alongside the formulation instead of being treated as independent downstream steps.
Targeting Ligands Disrupt Surface Properties
Adding antibodies, carbohydrates, peptides, aptamers, or other ligands can alter particle size, steric shielding, colloidal stability, and cellular interactions. We evaluate ligand presentation, PEG-lipid architecture, conjugation route, and surface density to reduce the risk of compromising the underlying LNP.
Our siRNA Lipid Nanoparticle Services
We provide modular siRNA-LNP development services for early formulation screening, delivery-system comparison, targeted nanoparticle research, and preparation of characterized material for downstream studies. Project scope can range from evaluation of an existing formulation to development of a new lipid composition and process.
siRNA Payload Review
Capabilities include:
- Review of siRNA duplex length, sequence format, concentration, modification pattern, counterion, and supplied buffer
- Assessment of chemically modified, fluorescently labeled, single-target, or multi-siRNA payloads
- Evaluation of payload compatibility with acidic formulation conditions, solvent exposure, purification, and extraction-based analysis
- Planning for negative-control siRNA, reporter siRNA, or matched payload sets where comparative studies are required
- Coordination with fluorescently labeled siRNA services for uptake or distribution experiments
Customer value:
Early payload review helps prevent formulation work from being confounded by RNA integrity, concentration, labeling, or buffer-compatibility problems.
Lipid System Design
Capabilities include:
- Selection or comparison of ionizable lipids based on the intended siRNA payload and research model
- Evaluation of helper phospholipids, cholesterol or alternative sterols, and PEG-lipid structures
- Adjustment of lipid molar ratios and nitrogen-to-phosphate relationships
- Support for commercial lipids, customer-supplied lipids, and exploratory lipid candidates
- Integration with PEG-lipid synthesis and conjugation projects when a specialized surface component is needed
Deliverables:
A formulation plan defining candidate lipid systems, screening variables, process assumptions, analytical endpoints, and advancement criteria.
LNP Formulation Screening
Capabilities include:
- Rapid mixing of an ethanolic lipid phase with an aqueous siRNA phase under controlled conditions
- Screening of lipid ratios, charge ratio, siRNA concentration, pH, flow ratio, total flow rate, and mixing configuration
- Comparison of microfluidic, impingement-style, or small-scale batch approaches where appropriate
- Evaluation of particle size, polydispersity, encapsulation, recovery, and visual stability during lead selection
- Replicate preparation of selected candidates to assess process repeatability
Customer value:
Structured screening identifies formulation and process interactions that may be missed when individual variables are changed one at a time.
Purification & Buffering
Capabilities include:
- Removal of ethanol, unencapsulated siRNA, excess lipid, and low-molecular-weight formulation components
- Tangential-flow, dialysis, centrifugal, or chromatography-based processing depending on scale and particle behavior
- Buffer exchange into application-relevant aqueous systems
- Concentration adjustment and evaluation of material loss during downstream processing
- Assessment of aggregation or leakage introduced during purification, filtration, or storage preparation
Deliverables:
Purified siRNA-LNP material with documented buffer conditions, processing observations, and post-purification analytical results.
Targeted Surface Engineering
Capabilities include:
- Incorporation of functional PEG-lipids during particle assembly or through post-formation surface modification
- Evaluation of antibody, peptide, carbohydrate, aptamer, and small-molecule targeting ligands
- Selection of linker length and conjugation chemistry based on ligand stability and LNP surface accessibility
- Comparison of pre-conjugated lipid assembly and post-insertion approaches
- Coordination with antibody-conjugated LNP or GalNAc-LNP development programs where relevant
Focus areas:
Ligand accessibility, surface density, particle stability, nonspecific interactions, and retention of the original LNP characteristics.
Analytical Performance Testing
Capabilities include:
- Particle-size, polydispersity, zeta-potential, encapsulation, RNA-content, and RNA-integrity measurements
- Lipid-content or composition analysis using methods appropriate to the selected components
- Morphology assessment, apparent ionization behavior, and stress or storage evaluation where required
- Optional cellular uptake, reporter response, target-mRNA reduction, or protein-level knockdown studies
- Comparative analysis of formulation candidates using predefined advancement criteria
Deliverables:
Analytical summaries, candidate comparisons, functional observations where included, and recommendations for further optimization or scale transition.
Key Design Parameters for siRNA Lipid Nanoparticles
siRNA-LNP performance results from interactions among the RNA payload, lipid chemistry, particle composition, manufacturing process, and final use conditions. The following parameters should be considered together when designing a screening program.
| Design Parameter | Common Options | Development Questions | Potential Performance Impact | Customer Value |
| siRNA Payload | Unmodified or modified duplexes, labeled siRNA, siRNA mixtures, reporter or control sequences | Is the duplex stable under formulation, purification, extraction, and storage conditions? | Influences encapsulation, integrity, release, knockdown, and analytical recovery | Ensures the delivery system is developed around the actual payload rather than a nonrepresentative surrogate |
| Ionizable Lipid | Commercial ionizable lipids, customer-supplied candidates, exploratory amino lipids | Does the lipid support RNA association during formulation and productive release after uptake? | Strongly affects encapsulation, particle structure, ionization behavior, uptake, and intracellular delivery | Provides a rational basis for comparing candidate delivery systems |
| Helper Lipid & Sterol | Saturated or unsaturated phospholipids, fusogenic helper lipids, cholesterol, alternative sterols | Which components best support particle structure, membrane interaction, and stability? | Can alter particle organization, membrane fusion, leakage, and storage behavior | Helps resolve formulations that encapsulate well but perform poorly in functional studies |
| PEG-Lipid Design | Different PEG lengths, lipid anchors, molar percentages, and functional end groups | How much steric stabilization is required without excessively limiting cellular interaction? | Influences particle size, aggregation, protein adsorption, circulation behavior, and ligand presentation | Supports balanced stability and accessibility for the intended experiment |
| Charge Relationship | Multiple nitrogen-to-phosphate ratios and total lipid-to-siRNA conditions | What input ratio provides adequate loading without creating undesirable particle characteristics? | Affects encapsulation, recovery, surface behavior, particle size, and functional response | Prevents selection based on encapsulation alone |
| Mixing Process | Microfluidic mixing, impingement mixing, T-junction mixing, small-scale ethanol injection | Which flow ratio, mixing rate, concentration, and geometry produce reproducible particles? | Controls nucleation, particle growth, size distribution, loading, and batch consistency | Establishes process parameters that can be evaluated during scale transition |
| Final Buffer | Neutral aqueous buffers with project-specific salts, sugars, or stabilizing components | Does the formulation remain stable during handling, storage, and use in the selected biological system? | Influences aggregation, leakage, particle-size drift, and assay compatibility | Reduces downstream troubleshooting caused by an unsuitable delivery buffer |
siRNA-LNP Formulation and Surface Engineering Strategies
The appropriate preparation method depends on material availability, screening scale, desired process control, surface-functionalization needs, and the requirements of the downstream study. Method selection should therefore be made before defining the analytical and scale-up plan.
| Strategy | Technical Approach | Suitable Project Stage | Development Advantages | Key Considerations |
| Microfluidic Rapid Mixing | Ethanolic lipids and aqueous siRNA are combined in a controlled mixer with defined flow conditions | Formulation screening, lead optimization, and process-comparison studies | Provides controlled mixing and systematic adjustment of process variables | Mixer geometry, flow ratio, total flow rate, concentration, and solvent composition can all affect the result |
| Impingement or T-Junction Mixing | Two liquid streams are rapidly combined through confined or opposing flow paths | Process development and evaluation of alternative mixing equipment | Supports rapid self-assembly and can be assessed for larger preparation volumes | Direct transfer from another mixer format may change particle characteristics |
| Batch Ethanol Injection | Lipids in ethanol are introduced into an aqueous siRNA phase with controlled agitation | Feasibility studies and low-material exploratory screening | Simple setup and useful for early comparisons when material is limited | Mixing heterogeneity and operator dependence can limit reproducibility |
| Mixture-Process Screening | Lipid composition and manufacturing variables are studied within a structured experimental matrix | Lead optimization and identification of robust operating windows | Reveals interactions between composition and process parameters | Requires clear responses, factor ranges, controls, and advancement criteria |
| Pre-Functionalized Assembly | Ligand-bearing or reactive lipids are included in the initial lipid mixture before LNP formation | Targeted LNP screening when the functional lipid tolerates formulation conditions | Integrates the surface component directly into particle assembly | Ligand exposure, conjugate purity, and functional-lipid percentage must be controlled |
| Post-Insertion Modification | Functional PEG-lipids or ligand-lipid constructs are inserted into preformed siRNA-LNPs | Modular targeting studies and comparison of multiple surface ligands | Separates core LNP formation from the ligand-decoration step | Insertion efficiency, free ligand removal, particle stability, and surface density require verification |
Related delivery approaches and comparison points are discussed in our overview of siRNA delivery methods.
Analytical Characterization of siRNA Lipid Nanoparticles
siRNA-LNP characterization should establish more than particle formation. A useful analytical package evaluates whether the formulation contains intact siRNA, maintains acceptable physical properties, survives downstream processing, and supports the intended functional experiment.
| Analytical Category | Possible Methodology | Development Purpose | Typical Data Delivered |
| Particle Size & Distribution | Dynamic light scattering or another suitable particle-sizing method | Monitoring average hydrodynamic size, polydispersity, aggregation, and batch variation | Size, PDI, distribution summaries, and candidate comparisons |
| siRNA Encapsulation | Fluorescence-based exclusion assay, chromatography, or another validated comparison of free and total siRNA | Determining the fraction of siRNA protected within or associated with the LNP | Encapsulation results, total-siRNA estimates, and recovery calculations where included |
| siRNA Integrity | Gel electrophoresis, capillary electrophoresis, or chromatography after suitable extraction | Checking whether formulation, purification, storage, or extraction damages the duplex | Integrity profiles and comparison with the starting siRNA |
| Surface Charge & Ionization | Zeta-potential analysis and apparent ionization-response assays where appropriate | Evaluating surface-state changes and formulation behavior across pH conditions | Zeta-potential values, titration trends, and formulation comparisons |
| Lipid Composition | HPLC, charged-aerosol detection, LC-MS, or another component-appropriate method | Confirming lipid presence, relative composition, degradation, or process-related losses | Lipid-content or ratio summaries based on the agreed analytical scope |
| Particle Morphology | Cryogenic or conventional electron microscopy where required | Reviewing particle shape, gross structure, and aggregation not fully described by bulk sizing | Representative images and morphology observations |
| Stability Evaluation | Time-point testing, freeze-thaw evaluation, dilution challenge, or exposure to application-relevant media | Identifying size drift, aggregation, leakage, RNA loss, or reduced functional response during handling | Comparative stability data and recommended handling windows |
| Functional Performance | Cellular uptake, reporter silencing, target-mRNA analysis, or protein-level knockdown | Determining whether physicochemical quality translates into useful siRNA delivery | Candidate-ranking data and observations relevant to the selected cell model |
Workflow for Custom siRNA-LNP Development
Project Definition & Material Review
We review the siRNA sequence format, chemical modifications, available quantity, supplied buffer, target cell model, intended study, and existing formulation data. This defines whether the project requires feasibility testing, formulation rescue, comparative screening, or full method development.
Formulation Strategy & Screening Plan
Candidate ionizable lipids, helper components, PEG-lipids, composition ranges, charge relationships, mixing variables, purification methods, and analytical endpoints are organized into a project-specific screening plan.
siRNA-LNP Preparation
Lipid and siRNA phases are prepared and combined under controlled mixing conditions. Initial candidates are assessed for visible stability, particle size, polydispersity, encapsulation, and material recovery before advancement.
Purification & Buffer Exchange
Selected formulations are processed to remove ethanol, free siRNA, and other unwanted components. The buffer and concentration are adjusted for downstream testing while monitoring particle changes and processing losses.
Analytical & Functional Evaluation
Candidate formulations are characterized using the agreed physicochemical methods. Where included, cellular uptake and gene-knockdown studies are used to determine whether analytical quality translates into functional delivery.
Lead Selection & Scale Support
Results are reviewed against project-specific criteria, and selected formulations can be repeated at increased scale. Process parameters, buffer conditions, analytical findings, and handling recommendations are documented to support subsequent research.
Why Choose Our siRNA-LNP Development Services
Payload-to-Formulation Matching
The formulation strategy is built around the actual siRNA duplex, modification pattern, concentration, target model, and study objective. This reduces the risk of selecting a carrier using a surrogate payload that behaves differently from the final research material.
Integrated Process Control
Lipid ratios, charge relationships, concentrations, mixing conditions, purification, and buffer selection are evaluated as interacting variables. This provides more useful development information than optimizing a single formulation metric in isolation.
Analytics Linked to Function
Particle size and encapsulation are interpreted together with siRNA integrity, stability, surface behavior, and optional knockdown results. This helps distinguish particles that are merely well formed from those worth advancing into delivery studies.
Flexible Research Scale
Projects can begin with low-material feasibility work and progress through expanded screening, repeat-batch evaluation, surface functionalization, and increased preparation scale without forcing every program into the same workflow.
Research Applications of siRNA Lipid Nanoparticles
Gene Knockdown Studies
- Delivery of target-specific siRNA for mRNA or protein-reduction experiments.
- Comparison of formulation-dependent knockdown in selected cell models.
- Preparation of matched active and negative-control siRNA-LNPs.
Difficult Cell Models
- Formulation screening for primary cells, suspension cells, or other models with poor response to standard transfection reagents.
- Evaluation of uptake, viability, and gene-silencing balance.
- Optimization of exposure concentration and treatment conditions.
Targeted Delivery Research
- Surface presentation of antibodies, peptides, carbohydrates, aptamers, or small-molecule ligands.
- Comparison of targeted and non-targeted LNP controls.
- Assessment of ligand density, accessibility, and effects on particle properties.
Combination siRNA Studies
- Co-formulation of multiple siRNA duplexes for pathway or multi-target research.
- Evaluation of payload-ratio effects on loading and functional response.
- Preparation of individual and combined formulations for comparative studies.
Uptake & Distribution Studies
- Formulation of fluorescent or otherwise traceable siRNA payloads.
- Cell-association, internalization, trafficking, and distribution experiments.
- Comparison of labeled-payload behavior with functional knockdown results.
Formulation Benchmarking
- Comparison of lipid compositions, mixing methods, surface modifications, or final buffers.
- Investigation of batch variability and critical process parameters.
- Selection of lead candidates for expanded research programs.
Discuss Your siRNA Lipid Nanoparticle Project
Whether you need an initial siRNA-LNP feasibility study, optimization of an unstable formulation, comparison of ionizable lipid systems, preparation of targeted particles, or a broader characterization package, we can build the project around your payload, material availability, and downstream research requirements.
Contact our scientific team with your siRNA format, target model, desired preparation scale, preferred lipid components, and existing formulation data to request a project-specific development proposal.
Frequently Asked Questions (FAQ)
What information is needed to start an siRNA-LNP project?
Useful starting information includes the siRNA sequence or duplex format, chemical modifications, available quantity, concentration, supplied buffer, target cell model, intended study, desired scale, preferred lipids, and any previous formulation data.
Can you work with customer-supplied siRNA and lipids?
Yes. Projects may use customer-supplied siRNA, commercial lipid components, customer-supplied ionizable lipids, or a combination of supplied and sourced materials. Material compatibility is reviewed before formulation begins.
Which lipids are normally evaluated in an siRNA-LNP formulation?
A typical screening program considers an ionizable lipid, helper phospholipid, cholesterol or another sterol, and a PEG-lipid. Component identity and molar ratio are adjusted according to the payload and research objective.
How is siRNA encapsulation efficiency measured?
Encapsulation can be evaluated by comparing accessible siRNA with total siRNA after particle disruption. Fluorescence-based assays, chromatography, or other suitable methods may be used depending on the formulation and payload.
Does high encapsulation guarantee effective gene knockdown?
No. Productive knockdown also depends on siRNA integrity, particle stability, cellular uptake, endosomal processing, cytoplasmic release, and compatibility with the selected biological model.
